ADHD in the News 2023-11-30

Shortage of Adderall and other ADHD drugs expected to last through 2024, despite federal attempts to fix it

CLEVELAND, Ohio — The nationwide shortage of Adderall and related drugs, used to treat attention/deficit hyperactivity disorder, has passed the year mark with no end in sight. High demand — from increased access to the medication via telehealth to people with long COVID-19 using ADHD drugs — makes the situation worse.

Longer Use of ADHD Meds May Boost Heart Risk — Observational data suggest particular risk for hypertension and arterial disease

Longer use of attention deficit-hyperactivity disorder (ADHD) medication was associated with an increased risk of cardiovascular disease, particularly hypertension and arterial disease, a nested case-control study from Sweden showed.

People taking ADHD medications should closely monitor their heart health, study suggests

CNN — Long-term use of ADHD medications can raise the risk of cardiovascular disease in both children and adults, according to a study published Wednesday in JAMA Psychiatry. Experts say that the benefits of treatment still outweigh the risks for many, but heart heath should be carefully considered and monitored when making individual decisions.

Understanding subjective beliefs could be vital to tailoring more effective treatments for depression and ADHD

Summary: Taking into account whether people believe they are receiving a real treatment or a fake one (placebo) could provide better insights that could help improve interventions for conditions such as depression and ADHD.

Deep-Learning Model Shows Promise for ADHD Diagnosis in Teens — AI algorithm identified significant differences in nine brain white matter tracts

CHICAGO -- An artificial intelligence (AI) deep-learning model pinpointed significant differences in nine brain white matter tracts in adolescents with attention deficit-hyperactivity disorder (ADHD), researchers reported here.

Psychiatric Comorbidity Increases Risk for Schizophrenia With ADHD

THURSDAY, Nov. 30, 2023 (HealthDay News) -- The presence of psychiatric comorbidity in young patients with attention-deficit/hyperactivity disorder (ADHD) is associated with a higher risk for being diagnosed with schizophrenia, according to a study published online Nov. 30 in JAMA Network Open.

New study sheds light on ADHD’s impact on motivation and the efficacy of amphetamine-based meds

In a recent study published in the Journal of Neuroscience, researchers found that individuals with Attention-Deficit/Hyperactivity Disorder (ADHD) show reduced motivation to engage in effortful activities, both cognitive and physical, which can be significantly improved with amphetamine-based medications.

Microdosing psychedelics shows promise for improving mindfulness in adults with ADHD

Adults with attention deficit hyperactivity disorder (ADHD) or severe ADHD symptoms who practiced microdosing with psychedelics reported increases in mindfulness after four weeks, according to new preliminary research published in Frontiers in Psychiatry. The findings underscore the importance of conducting future placebo-controlled studies to validate whether these observed changes can be replicated in a controlled experimental environment.

Texas AG sues Pfizer over quality-control lapses in kids’ ADHD drug

Nov 20 (Reuters) - Texas Attorney General Ken Paxton accused Pfizer (PFE.N) and its supplier Tris Pharma of providing children's ADHD medicine that it knew might be ineffective to the state's Medicaid insurance program for low-income people, in a lawsuit unsealed on Monday.

US Limit on a Key ADHD Drug Is Worsening Shortages, Group Says

A US shortage of the new generic version of Vyvanse, an ADHD medication, is due in part to federal limits on production, according to an industry group representing generic drug makers. Manufacturers haven’t been able to secure enough raw material “to launch their products at full commercial scale,” according to a letter from the Association for Accessible Medicines addressed to the Drug Enforcement Administration, which sets the limits on production that the industry must follow.

WHO issues new and updated recommendations on treatment of mental, neurological and substance use conditions

The World Health Organization (WHO) has today published the third edition of the Mental Health Gap Action Programme (mhGAP) guideline which includes important new, and updated, recommendations for the treatment and care of mental, neurological and substance use (MNS) disorders. MNS disorders are major contributors to morbidity and premature mortality in all regions of the world. Yet it is estimated that over 75% of people with MNS disorders are unable to access the treatment or care they need.

Diagnosed With ADHD — What Should I Do Now?

Attention deficit hyperactivity disorder (ADHD) is a mental health condition involving one or more persistent symptoms: hyperactivity, impulsive behavior, or difficulty paying attention. Left untreated, ADHD can cause problems related to work, school, relationships, and self-esteem. The right treatment can help.

What it’s like to be diagnosed with ADHD as an adult in China

Vivian Li, 27, felt "relief" when she was diagnosed earlier this year with attention deficit hyperactivity disorder (ADHD). "A lot of the stress and mental baggage I had before suddenly disappeared … I just felt that there is hope," Ms Li said.